Genmab — Marts 2019

jkj

hvis det er direkte sammenlignelige tal, så er det vel ikke så godt for dara. ?

polle1

Godmorgen og god dag

E_L

read back the nov Q3 transcript back, answer to Citi analyst on BCMA. eg: Jan: actually, we were actually delighted to see the updated data. We don't feel very threatened by them at all

E_L

"And what is also encouraging is that Janssen recently, they also have a BCMA CD3 bispecific program using our DuoBody technology….& said in the business update that they intend to actually combine their BCMA CD3 bispecific together with daratumumab and not compete with daratumumab, and that is probably the right thing to do also for the BCMA ADC from Glaxo and potentially for Amgen's BCMA BiTE molecule."

peter12

Det var det EL linkede til i onsdags. Det er et lille studie (n=35) og kun friske patienter, da det nok er for giftigt til svagere...

Helge_LarsenPI-redaktør

Tak for reminderen E L.

gentogen

Lidt svært helt at gennemskue, men 54% af patienterne var "Stage I" og alle ECOG 0 eller 1 (70% 1). Tidligere behandlinger fra 1 til over 10. 14 en eller anden slags Dara behandling tidligere. Safety lidt svær at vurdere da procenterne er procenter af alle, selv om kun 22 af 35 gennemførte (så tallene kan være for små - måske). De fremhæver selv at dette er det hidtil bedste, der er set efter Dara

E_L

Genmab Announces European Regulatory Submission for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma

Company Announcement Type II variation application submitted to the EMA for daratumumab in combination with lenalidomide and dexamethasone as treatment...

GlobeNewswire News Room (www.globenewswire.com)

E_L

Genmab Announces European Regulatory Submission for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma

Sukkeralf

Nice

E_L

it remains strange to me that there is such a difference between US and european treatment regimen. I wonder if some day we'll see a head-to-head MAIA-Alcyone trial?

peter12

Now you can buy generic Revlimid in some european countries ?

jkj

Hvornår var det helt præcist at jannsen aflevere sidste data til fda ?

jkj

herfra skal vi vel regne med 4 uger ifølge rtor planen eller hvad ?

jkj

det var den 12 marts

jkj

tvivler på at de er hurtigere end skitseret, så i mellem 8 - 12 april

jkj

Men Seattle Genetics fik på under 14 dage efter sidst indlevering, så der er da en teoretisk risiko for cognac til kaffen i aften.

Tandfeen-2

Tror først det bliver efter påske

Legolas23

Darzalex har slået så mange rekorder, så mon ikke også godkendelsen kommer hurtigere end ventet.

E_L

Talking to The Pharma Letter, Janssen’s EMEA therapy area lead for hematology, Catherine Taylor, said: “I had commissioners coming up to me and telling me that “this is a game changer, this is going to change practice.” https://www.thepharmaletter.com/article/early-oncology-pacesetters-for-2019-will-seek-to-pick-up-where-janssen-left-on-in-2018